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http://dx.doi.org/10.1016/j.jmii.2012Background: Oropharyngeal candidiasis continues to be a major opportunistic infection in
human immunodeficiency virus (HIV)-infected patients. The objectives of this study were to
investigate the prevalence, associated factors, and microbiologic features for oropharyngeal
yeast colonization in HIV-infected patients.
Methods: From October to December 2009, consecutive HIV-infected patients older than 18
years were recruited in this study. Demographic information, underlying conditions, and clin-
ical histories were collected. Oropharyngeal swab cultures for yeasts and antifungal drug
susceptibilities of the isolates were performed.
Results: Of the 105 HIV-infected patients, 54 (51.4%) were colonized with yeasts, including
11 patients (20.4%) with more than one species. Among the 68 isolates, Candida albicans
accounted for 73.5%, followed by Candida tropicalis (5.9%), Candida glabrata (5.9%), and
Candida dubliniensis (4.4%). There were 7.5% and 6% Candida isolates resistant to fluconazole
and voriconazole, respectively. All of the Candida isolates were susceptible to amphotericin B.
A higher prevalence of yeast colonization was noted in patients with a CD4 cell count, Jiau-Shu, Yan-Chau, Kaohsiung 824, Taiwan.
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130 J.-N. Lin et al.200 cells/mL (p Z 0.032). Multivariate regression analysis showed that intravenous drug use
was an independent associated factor for oropharyngeal yeast colonization (odds ratio, 5.35;
95% confidence interval, 1.39e20.6; pZ 0.015), as well as protease inhibitor-containing anti-
retroviral therapy (odds ratio, 3.59; 95% confidence interval, 1.41e9.12; p Z 0.007).
Conclusion: Despite previous studies showing that protease inhibitors decreased Candida
adhesion to epithelial cells in vitro, the current study found protease inhibitor-containing anti-
retroviral therapy predisposed to oropharyngeal yeast colonization in HIV-infected patients.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Human immunodeficiency virus (HIV)-infected patients are
prone to opportunistic infections with the progression of
cell-mediated immunodeficiency. Mucosal fungal infection,
especially oropharyngeal and esophageal candidiasis, is one
of the most common manifestations of HIV infections.1,2
More than 80% of patients had oropharyngeal colonization
by Candida species during the course of HIV infection.3,4
Despite the introduction of highly active antiretroviral
therapy since 1996, Candida species continue to be a major
pathogen for HIV-infected patients.5,6
Several virulent factors are involved in the pathogenesis
of Candida. In particular, secreted aspartic proteinases
(which are encoded by the SAP gene family and are
responsible for adherence, tissue damage, assimilating
nitrogen from proteinaceous sources, and evasion of host
immune responses) play a key role in the pathogenesis of
Candida.7 Interestingly, the secreted aspartic proteinase of
Candida and the HIV protease both belong to the aspartyl
proteinase family.8,9 The resolution of oral candidiasis in
HIV-infected patients was observed in clinical studies after
the introduction of protease inhibitors (PIs).10,11 However,
there are limited clinical studies comparing the effect of
PIs with other antiretroviral agents on oropharyngeal
carriage of Candida.
Although oral colonization of yeasts in HIV-infected
patients has been reported, the comprehensive associated
factors, such as underlying illnesses, modes of HIV trans-
mission, the past antimicrobial agents history, and current
antiretroviral regimens, have not been extensively investi-
gated. These factors are likely to influence the manifesta-
tion of oropharyngeal yeast colonization. To address these
issues and to better understand the epidemiology, we
conducted a prospective cross-sectional study to survey
the prevalence of oropharyngeal yeast colonization in
HIV-infected patients from industrial metropolitan areas in
Taiwan. We also determined the in vitro susceptibilities of
these isolates to fluconazole, voriconazole, and ampho-
tericin B.
Methods
Study setting
This study was carried out at E-Da Hospital, which serves
more than one million residents in the industrial metro-
politan areas and is a major referral hospital for HIV care insouthern Taiwan. This study was approved by the Institu-
tional Review Board of E-Da Hospital (EMRP-098-027).
Study protocol
From October to December 2009, consecutive HIV-infected
patients older than 18 years in the outpatient unit of E-Da
Hospital were evaluated. If oropharyngeal candidiasis was
noted, these patients were excluded from our study.
Demographic information about age and sex, underlying
illnesses, clinical conditions, the history of antibiotics and
antifungal therapy in the past 6 months, status of hospi-
talization in the past 12 months, and the use of anti-
retroviral agents was collected from medical records in
a standardized data form. Plasma HIV viral load and CD4
lymphocyte count were also determined at the time of data
collection.
Sample collection and culture
Oropharyngeal samples were obtained by swabbing the
oropharyngeal mucosa of patients with a dry cotton swab
(EZ Culturette; Becton Dickinson, Sparks, MD, USA). All
swabs were streaked onto Chromagar Candida medium
(CHROMagar Microbiology, Paris, France) and incubated at
30C for 72 hours. Three (if there were) independent
colonies from each positive culture were collected. Addi-
tional colonies were selected when the cultures had more
than one morphotype present. To distinguish Candida
albicans from Candida dubliniensis, all isolates were sub-
jected to VITEK Yeast Biochemical Card (YBC, bioMe´rieux,
Marcy l’Etoile, France). When the YBC identification prob-
ability was less than 90% or when uncommon species were
reported, the sequences of the internal transcribed spacer
(ITS) region and/or the D1/D2 region of ribosomal DNA
were used for species identification. The ITS regions
were amplified by the primers ITS1, 50-TCCGTAGGT
GAACCTGCGG-3, and ITS4 50-TCCTCCGCTTATTGATATGC-30,
and the D1/D2 regions were amplified by the primers
NL1 50-GCATATCAATAAGCGGAGGAAAAG-30 and NL4 50-
GGTCCGTGTTTCAAGACGG-30.12
Antifungal susceptibility tests
Minimum inhibitory concentrations (MICs) of fluconazole,
voriconazole, and amphotericin B were determined by the
broth microdilution method following the guidelines of the
Clinical and Laboratory Standards Institute (CLSI).13 Briefly,
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(range, 0.125e64 mg/mL), voriconazole (range,
0.0156e8 mg/mL), and amphotericin B (range,
0.0313e16 mg/mL) in RPMI medium 1640 (31800-022, Gibco
BRL) were used. After incubation at 35C for 48 hours, the
growth of each isolate was measured by Biotrak II plate
spectrophotometric reader (Amersham Biosciences, Bio-
chrom Ltd., Cambridge, England). Following the guidelines
of CLSI document M27-A3,13 isolates were considered
resistant to fluconazole, voriconazole, and amphotericin B
if their MICs were 64 mg/mL,  4 mg/mL, and 2 mg/mL,
respectively. Quality control strains included C. albicans
ATCC 90028, Candida krusei ATCC 6258, Candida para-
psilosis ATCC 22019, and Candida tropicalis ATCC 750. The
MICs at which 50% and 90% of the total population were
inhibited were defined as MIC50 and MIC90, respectively.
Data analysis
SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was used for
the analysis of results. Categorical variables were analyzed
using the c2 test or Fisher exact tests, as appropriate.
Continuous variables were analyzed using the Student
t-test. To identify the associated factors, underlying
conditions that could contribute to oropharyngeal coloni-
zation of yeasts and were associated with a level of
significance of <0.20 in univariate analyses were included
in a logistic regression model for multivariate analysis. Odds
ratio (OR), 95% confidence interval (CI), and p value were
calculated for each factor. Hosmer-Lemeshow goodness-of-
fit test was used to assess the fitness of the model. All p
values were two-tailed and p < 0.05 was considered
statistically significant.
Results
During the study period, 105 consecutive HIV-infected
patients were enrolled in this study. There were 99 males
(94.3%) and 6 females (5.7%), with a mean  standard
deviation (SD) age of 39.5  10.1 years (range, 20e70
years). Only three patients had a history of antibiotics or
antifungal use (duration, 3e6 months and 7e130 days,
respectively). The duration of HIV infection was 5.9  4.3
years (mean  SD). Use of intravenous drugs was found in
17 patients (16.2%) (Table 1).
Among these 105 HIV-infected patients, 54 (51.4%) were
colonized with yeasts. There were no significant differ-
ences in age, sex, underlying illness, antibiotics or anti-
fungal therapy within the previous 6 months, duration of
HIV infection, or a high HIV viral load (> 50 copies/mL)
between yeast culture-positive and -negative patient
groups. However, a history of hospitalization within the
previous 12 months (p Z 0.027) and a CD4 cell count
200 cells/mL (p Z 0.032) were significantly associated
with positive yeast cultures (Table 1). The prevalence of
positive oropharyngeal cultures also differed significantly
according to the modes of HIV transmission (pZ 0.031) and
regimens of antiretroviral therapy (p Z 0.022).
Multivariate regression analysis demonstrated that
intravenous drug use was an independent associated factor
for oropharyngeal yeast colonization when compared withmale homosexuality (OR, 5.35; 95% CI, 1.39e20.6;
p Z 0.015; Table 2) in regard to the mode of HIV trans-
mission. Patients who received PI/nucleoside reverse
transcriptase inhibitors (NRTIs) were more likely to be
associated with oropharyngeal yeast colonization than
those who received nonnucleoside reverse transcriptase
inhibitor (NNRTI)/NRTIs (OR, 3.59; 95% CI, 1.41e9.12;
p Z 0.007). Further analysis demonstrated that
the difference of colonization rate between PI- and
NNRTI-containing regimens was independent of the CD4 cell
count and plasma HIV viral load (p Z 0.804 and 0.228,
respectively).
Of the 68 yeasts isolated from the 54 patients, 67 were
Candida species (Table 3). Multiple yeast species were
identified in 11 patients (20.4%), including eight patients
with two species and three with three species. C. albicans
accounted for 73.5% of the isolates, followed by C. tropi-
calis (5.9%), Candida glabrata (5.9%), and C. dubliniensis
(4.4%). Neither mode of HIV transmission (p Z 0.999) nor
antiretroviral regimens (pZ 0.611) was associated with the
species of isolates.
The results of susceptibility tests are shown in Table 3.
Of the 67 Candida isolates, 7.5% were resistant to fluco-
nazole and 6% were resistant to voriconazole. All Candida
isolates were susceptible to amphotericin B. The five
fluconazole-resistant isolates included two C. tropicalis
and one each of C. albicans, C. glabrata, and Candida
krusei. Among the four voriconazole-resistant isolates, two
were C. albicans and the others were C. tropicalis. One
C. albicans and two C. tropicalis were cross-resistant to
both fluconazole and voriconazole. There was no statisti-
cally significant difference between the CD4 counts and
the susceptibility to fluconazole (susceptible, 452  271;
nonsusceptible, 339  108; p Z 0.362) and voriconazole
(susceptible, 452  269; nonsusceptible, 310  182;
p Z 0.301).
Among five patients receiving antimicrobial drugs
6 months before the survey, one had antibiotic and anti-
fungal drug, two had antibiotic, and two had antifungal
drug. The duration for antibiotics ranged from 90 to 180
days and for antifungal drugs ranged from 7 to 130 days.
Four of the five patients were colonized by yeasts. Candida
isolates were susceptible to fluconazole despite the fact
that they were recovered from patients receiving flucona-
zole therapy before the survey.Discussion
As the disease progresses, HIV-infected patients become
more vulnerable to a variety of opportunistic infections,
including candidiasis. The prevalence of oropharyngeal
yeast colonization in HIV-positive patients varies from 44%
to 62% in the antiretroviral therapy era.5,14e16 In the
current study, 51.4% of HIV-infected patients had yeast
colonization in the oropharyngeal cavity. We also
found a higher rate of oropharyngeal yeast colonization in
HIV-positive patients if their CD4 lymphocyte counts were
200 cells/mL. This finding is similar to that of previous
studies.3,14,16 In addition to the low CD4 lymphocyte count,
several other factors could influence the occurrence and
distribution of oropharyngeal yeast colonization.
Table 1 Demographic characteristics, underlying illnesses, laboratory findings, and medication histories of HIV-infected
patients
Characteristics All cases Yeast culture p
Positive (n Z 54), n (%) Negative (n Z 51), n (%)
Age, mean  SD (y) 39.5  10.1 40.8  11 38.1  8.8 0.171
Sex, male 99 (94.3) 50 (92.6) 49 (96.1) 0.679
Underlying illness
Diabetes mellitus 7 (6.7) 4 (7.4) 3 (5.9) 0.999
Hypertension 3 (2.9) 2 (3.7) 1 (2) 0.999
Modes of HIV transmission 0.031
Homosexual 60 (57.1) 25 (46.3) 35 (68.6)
Heterosexual 28 (26.7) 16 (29.6) 12 (23.5)
Intravenous drug use 17 (16.2) 13 (24.1) 4 (7.8)
Hospitalization within the previous 12 mo 6 (5.7) 6 (11.1) 0 0.027
Antibiotics therapy within the previous 6 mo 3 (2.9) 2 (3.7) 1 (2) 0.999
Antifungal therapy within the previous 6 mo 3 (2.9) 3 (5.6) 0 0.243
HIV infection
Duration of HIV infection (y) 5.9  4.3 6.1  4.3 5.7  4.3 0.627
HIV viral load > 50 copies/mL 26 (24.8) 16 (29.6) 10 (19.6) 0.234
CD4 count (cells/mL) 480  258 455  265 508  250 0.294
CD4 count  200 cells/mL 9 (8.6) 8 (14.8) 1 (2) 0.032
Antiretroviral therapy 0.022
NNRTI þ 2 NRTIs 46 (43.8) 16 (29.6) 30 (58.8)
Duration, mean  SD (mo) 33.9  21.7 26.6  21 37.8  21.3 0.094
Protease inhibitor þ 2 NRTIs 46 (43.8) 30 (55.6) 16 (31.4)
Duration, mean  SD (mo) 41  21.9 38.4  23.6 45.9  18 0.238
Integrase inhibitor þ 2 NRTIs 4 (3.8) 2 (3.7) 2 (3.9)
Duration (mo) 3, 3, 9, 38 3, 38 3, 9
Three NRTIs 1 (1) 0 1 (2)
Duration (mo) 61 d 61
None 8 (7.6) 6 (11.1) 2 (3.9)
CI Z confidence interval; HIV Z human immunodeficiency virus; NNRTI Z nonnucleoside reverse transcriptase inhibitor;
NRTI Z nucleoside reverse transcriptase inhibitor; OR Z odds ratio; SD Z standard deviation.
132 J.-N. Lin et al.Phelan et al17 and Lamster et al18 reported a much
higher prevalence rate of oral Candida infection in intra-
venous drug users than in homosexual men. Even in sero-
negative patients, a higher percentage of oral candidiasis
was observed among intravenous drug users.18,19 Opioids,
particularly morphine and its derivatives, have been shown
to depress the immune system by influencing the function
of T lymphocytes.20 Therefore, in HIV-infected patients
who also receive injections of opioids, their immunity could
be further depressed by the dual effect of opioids and HIV.
In the current study, we found the prevalence of oropha-
ryngeal yeast colonization was significantly higher in HIV
seropositive intravenous drug users than in homosexual
men. This observation lends further support to the immu-
nosuppressive effect of opioids in HIV-infected patients.
Nevertheless, whether abuse of opoids is detrimental to
immunity needs further investigation.
PI, an important component of highly active anti-
retroviral therapy, blocks the action of the HIV protease,
which is required for protein processing in the viral
replication cycle.21 In vitro studies demonstrated that PIs
could inhibit secreted aspartic proteases of C. albicans andconsequently attenuate their adherence to epithelial cells,
interrupt the integrity of yeast cell membrane, and
decrease the viability of Candida.9,22e24 These results
suggested that the reduction of oral Candida colonization in
HIV-infected patients who received antiretroviral therapy
might not only be due to reconstitution of the immune
system, it could also result from the effect of direct inhi-
bition to secreted aspartic proteases by PIs.9,22,23
Despite these in vitro studies, there is limited literature
comparing the clinical differences of antiretroviral regi-
mens on the prevalence of oropharyngeal yeast coloniza-
tion in HIV-infected patients.16,25,26 Cassone et al25 found
that PI-containing antiretroviral therapy exerted an early,
immune reconstitution-independent effect on attenuation
of oral candidiasis compared with NNRTI-containing
regimens. Pomarico et al26 investigated the effect of
antiretroviral therapy on oral candidiasis and found that PI-
containing regimens reduced the prevalence rate of oral
candidiasis in HIV-positive children. However, Delgado
et al16 reported that PI-containing regimens exerted no
different effect on the oral carriage of Candida when
compared with NNRTI-containing regimens. Interestingly,
Table 2 Multivariate logistic regression model of associ-
ated factors for oropharyngeal yeast colonization in HIV-
infected patientsa
Associated factors OR (95% CI) p
Modes of HIV transmission
Homosexual 1 (Reference) d
Heterosexual 2.01 (0.76e5.35) 0.162
Intravenous drug use 5.35 (1.39e20.6) 0.015
Hospitalization within the
previous 12 months
No 1 (Reference) d
Yes d 0.999
Antiretroviral therapy
NNRTI þ 2 NRTIs 1 (Reference) d
Protease inhibitor
þ 2 NRTIs
3.59 (1.41e9.12) 0.007
Integrase inhibitor
þ 2 NRTIs
2.33 (0.28e19.39) 0.434
Three NRTIs d 0.999
None 5.23 (0.84e32.69) 0.077
CI Z confidence interval; HIV Z human immunodeficiency
virus; NNRTI Z nonnucleoside reverse transcriptase inhibitor;
NRTI Z nucleoside reverse transcriptase inhibitor; OR Z odds
ratio.
a All variables were entered into the model in one single step.
Table 3 The minimum inhibitory concentrations of antifungal a
Isolates
Fluconaz
Candida albicans (n Z 50)
Range 0.125e64
MIC50 0.25
MIC90 1
Candida tropicalis (n Z 4)
Range 0.5e64
MIC50 1
MIC90 64
Candida glabrata (n Z 4)
Range 8e64
MIC50 8
MIC90 64
Candida dubliniensis (n Z 3)
Range 0.125e0.
MIC50 0.125
MIC90 0.25
Candida parapsilosis (n Z 2) 0.5e2
Candida krusei (n Z 1) 64
Candida utilis (n Z 1) 2
Candida guilliermondii (n Z 1) 1
Candida (Stephanoascus) ciferrii (n Z 1) 0.125
Geotrichum klebahnii (n Z 1) d
HIV Z human immunodeficiency virus; MIC Z minimum inhibitory co
Yeast colonization in HIV-infected patients 133the current study demonstrated that the prevalence of
yeast colonization in oropharyngeal cavity was significantly
higher in patients receiving PI-containing antiretroviral
therapy than in those with NNRTI-containing regimens.
Moreover, this difference was independent of the patients’
CD4 cell count and plasma HIV viral load. However, all of
these clinical studies, including the current report, were
not randomized, double-blind, parallel-group investiga-
tions. To better understand the influence of different
antiretroviral regimens on the distribution of oropharyngeal
Candida colonization in HIV-infected patients, further well-
designed head-to-head comparison studies are warranted.
Although C. albicans is still the most common species,
the prevalence of Candida species other than C. albicans
isolated from HIV-infected patients is increasing.3,4,14,27
C. dubliniensis, C. glabrata, and C. tropicalis are consid-
ered as emerging pathogens.14,27,28 Compared with the
current study with a proportion of 73.5%, the percentage of
C. albicans decreased from 86.7% in 200214 to 68.5% in
200527 in Taiwan. The widespread use of antiretroviral
agents, antibiotics, and antifungal agents were assumed to
have an effect on the distribution of oropharyngeal yeast
colonization.5,29 Since the introduction of highly active
antiretroviral therapy, there was a significant decline of
fluconazole- and itraconazole-resistant Candida colonizing
the oral cavity of HIV-infected patients.30 In the current
study, the susceptibility of Candida to antifungal agents
was similar to previous reports in Taiwan.14,27 Because
Candida species other than C. albicans are known to have
higher resistant rates to antifungal agents,30 thesegents for isolated yeasts in HIV-infected patients
Minimum inhibitory concentration (mg/mL)
ole Voriconazole Amphotericin B
0.016e8 0.5e1
0.016 0.5
0.06 1
0.016e8 0.5e1
0.03 0.5
8 1
0.25e0.5 0.5e1
0.5 1
0.5 1
25 0.016 0.25
0.016 0.25
0.016 0.25
0.016e0.06 0.5e0.5
0.25 1
0.25 0.5
0.03 0.5
0.016 0.25
d d
ncentration.
134 J.-N. Lin et al.gradually increasing species may constitute an important
issue in the treatment of opportunistic infections among
HIV-infected patients.
There are several limitations to our study. First, this
study was conducted only at a single hospital in southern
Taiwan, limiting its generalizability. Second, the duration
of our study was only 3 months and the number of enrolled
cases was small. Therefore, the strength of our study could
be influenced. Third, the underlying illnesses were
collected from medical records. There may be inconsis-
tencies with the completeness of these data. Some asso-
ciated factors may not have been detected or explored in
our study.
In conclusion, the current study found a higher preva-
lence of oropharyngeal yeast colonization in HIV-infected
patients with a low CD4 cell count. Intravenous drug use
and PI-containing antiretroviral therapy were significantly
associated with oropharyngeal yeast colonization indepen-
dent of the CD4 cell count and HIV viral load. Although
C. albicans was still the prevalent species colonizing the
oropharyngeal cavity of HIV-infected patients, the
increasing multidrug-resistant Candida species other than
C. albicans present an emerging challenge in fungal infec-
tion management.Acknowledgments
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